Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
Oncocyte (OCX) will release its Q4 and full-year 2023 financial results on April 12, 2024. A conference call and webcast will be held to discuss the results.
04/09/2024 - 04:05 PM
Conference Call and Webcast on Friday, April 12, 2024, at 5:00 a.m. PT / 8:00 a.m. ET
IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial results and highlights.
Interested parties may access the live call via telephone by dialing toll free (888) 550-5422 for both domestic and international callers. Once dialed in, ask to be joined to the Oncocyte Corporation call.
The live webcast of the call may be accessed by visiting the “Events & Presentations” section of the Company’s website at https://investors.oncocyte.com
CONFERENCE CALL DETAILS
Webcast https://events.q4inc.com/attendee/233145459
About Oncocyte
Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test, GraftAssure™ is a research use only blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
Contact: jramson@pcgadvisory.com
When will Oncocyte release its Q4 and full-year 2023 financial results?
Oncocyte will release its Q4 and full-year 2023 financial results on April 12, 2024.
What is the ticker symbol for Oncocyte ?
The ticker symbol for Oncocyte is OCX.
How can interested parties access the conference call and webcast?
Interested parties can access the conference call by dialing toll-free (888) 550-5422 or by visiting the 'Events & Presentations' section of the company's website at https://investors.oncocyte.com.
Will there be a replay of the webcast available?
Yes, a replay of the webcast will be available on the company's website shortly after the conclusion of the call.
Oncocyte Corporation
NASDAQ:OCX
OCX Rankings
#5367 Ranked by Stock Gains
OCX Stock Data
Industry
In-Vitro Diagnostic Substance Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, In-Vitro Diagnostic Substance Manufacturing
Country
US
City
Irvine
About OCX
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
